NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (Nasdaq: EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.
"Genpact's deep expertise in the life sciences and healthcare sectors enables us to leverage extensive knowledge alongside our capabilities in data, technology, and AI. This combination allows us to drive positive outcomes and provide innovative solutions tailored to our clients' needs," said Balkrishan "BK" Kalra, President and CEO, Genpact. "Together, we are dedicated to realizing embecta's mission - to develop and provide solutions that make life better for people living with diabetes – and furthering Genpact's purpose: the relentless pursuit of a world that works better for people."
Genpact initially supported embecta's spin-off from BD and over time, the partnership has evolved to modernize embecta's operations. More specifically, Genpact supported the implementation of a robust ERP and launched an operating model with standardized global processes to meet the needs of a newly formed medical device company. Additionally, Genpact established end-to-end HR, finance, and procurement processes. This provided uninterrupted customer support and supply chain stability enabling embecta to continue providing insulin injection devices to 30 million people in more than 100 countries without interruption.
"From the beginning, our relationship was rooted in shared values and a commitment to mutual success," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer, embecta. "Our seamless collaboration resulted in the successful transition of embecta to an independent entity, ensuring a continuous flow of goods and working capital, maintaining supply chain continuity, and providing critical support for our customers and the people they serve."
Visit here for more information about Genpact's work in the healthcare industry.
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook.
MEDIA CONTACT:
Siya Belliappa
Genpact Media Relations
+1 7185619843
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$19.92 |
| Daily Change: | 0.10 0.50 |
| Daily Volume: | 518,633 |
| Market Cap: | US$1.160B |
September 03, 2024 August 09, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
